|
1.
|
原著(症例報告除く)
|
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study 2024/12
|
|
2.
|
その他
|
Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers 2024/10
|
|
3.
|
原著(症例報告除く)
|
Aspiration pneumonia after SARS-CoV-2 Omicron infection frequently induced physical functional decline in Japan 2024/08
|
|
4.
|
その他
|
Aspiration pneumonia was the most frequent cause of death in older patients with SARS-CoV-2 omicron-related pneumonia in Japan 2024/07
|
|
5.
|
原著(症例報告除く)
|
Comparison of pneumonia severity scores for COVID-19 patients with the Omicron variant 2024/05
|
|
6.
|
原著(症例報告除く)
|
Invalidity of JRS atypical pneumonia prediction score in Omicron variant of COVID-19 pneumonia 2024/05
|
|
7.
|
原著(症例報告除く)
|
Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease 2024/04
|
|
8.
|
原著(症例報告除く)
|
Functional decline at 1 year in hospitalized elderly pneumonia with SARS-CoV-2 Omicron variant: Comparison with the ancestral strain and Alpha variant 2024/04
|
|
9.
|
原著(症例報告除く)
|
Is the JRS atypical pneumonia prediction score useful in detecting COVID-19 pneumonia under nursing or healthcare settings? 2024/04
|
|
10.
|
原著(症例報告除く)
|
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study) 2024/02
|
|
11.
|
原著(症例報告除く)
|
IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study 2024/02
|
|
12.
|
その他
|
Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study 2024/02
|
|
13.
|
症例報告
|
Successful treatment of Dara sc-CyBorD in a patient with AL amiyloidosis and severe heart failure 2024/02
|
|
14.
|
原著(症例報告除く)
|
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum 2023/11
|
|
15.
|
原著(症例報告除く)
|
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum 2023/11
|
|
16.
|
症例報告
|
Efficacy of Gefapixant, a P2X3 Antagonist, for Refractory Atopic Cough 2023/09
|
|
17.
|
症例報告
|
Efficacy of gefapixant, a P2X3 antagonist, for lung cancer-related cough: a case report 2023/08
|
|
18.
|
原著(症例報告除く)
|
Venetoclaxを投与した再発又は難治性慢性リンパ性白血病/小リンパ球性リンパ腫患者における腫瘍崩壊症候群の発現状況 2023/08
|
|
19.
|
症例報告
|
Alectinib in a patient with ALK-positive non-small lung cancer unable to swallow capsules 2023/07
|
|
20.
|
症例報告
|
Anti-MDA-5 Antibody-positive Dermatomyositis after Allogeneic Bone Marrow Transplantation for Acute Transformation of Chronic Myelogenous Leukemia. 2023/07
|
|
21.
|
原著(症例報告除く)
|
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections 2023/05
|
|
22.
|
原著(症例報告除く)
|
Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus 2023/05
|
|
23.
|
原著(症例報告除く)
|
Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study 2023/05
|
|
24.
|
原著(症例報告除く)
|
Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan 2023/05
|
|
25.
|
原著(症例報告除く)
|
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin 2023/03
|
|
26.
|
原著(症例報告除く)
|
Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study 2023/03
|
|
27.
|
その他
|
【新リンパ腫学-基礎・臨床の最新動向-】悪性リンパ腫診療に求められる疾患背景因子の基礎知識 医原性免疫不全に関連するリンパ増殖症 2023/03
|
|
28.
|
原著(症例報告除く)
|
Association of High Mobility Group Box-Protein 1 and Platelet Microparticles in Patients After Hematopoietic Stem Cell Transplantation 2023
|
|
29.
|
原著(症例報告除く)
|
Clinical significance of oxidized LDL in patient with type 2 diabetes 2022/12
|
|
30.
|
原著(症例報告除く)
|
Monocyte or white blood cell counts and β(2) microglobulin predict the durable efficacy of daratumumab with lenalidomide 2022/12
|
|
31.
|
総説
|
Procoagulant platelets and hemostasis 2022/12
|
|
32.
|
原著(症例報告除く)
|
肺癌との鑑別を要した肺クリプトコッカス症の一例 2022/12
|
|
33.
|
原著(症例報告除く)
|
Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study 2022/11
|
|
34.
|
その他
|
【健康長寿と人参養栄湯】がん治療と人参養栄湯 多発性骨髄腫治療における疲労・倦怠感の改善効果 人参養栄湯の一つのポテンシャル 2022/10
|
|
35.
|
その他
|
【骨髄腫と類縁疾患-全身をみわたす診断・治療】骨髄腫に対する治療薬・治療法の特徴 プロテアソーム阻害薬 2022/10
|
|
36.
|
原著(症例報告除く)
|
Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract 2022/09
|
|
37.
|
原著(症例報告除く)
|
Real-world efficacy of letermovir prophylaxis for cytomegaloviru infections after allogeneic hematopoietic stem cell transplantations: A single-center retrospective analysis 2022/09
|
|
38.
|
原著(症例報告除く)
|
Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study 2022/07
|
|
39.
|
原著(症例報告除く)
|
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis 2022/06
|
|
40.
|
原著(症例報告除く)
|
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy 2022/04
|
|
41.
|
その他
|
【多発性骨髄腫および類縁疾患の病態解析と治療の進歩】多発性骨髄腫における維持療法の理論的背景 Total therapyから考える維持療法 2022/04
|
|
42.
|
原著(症例報告除く)
|
Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study 2022/02
|
|
43.
|
その他
|
Procoagulant platelets: generation and function 2021/11
|
|
44.
|
原著(症例報告除く)
|
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation 2021/08
|
|
45.
|
原著(症例報告除く)
|
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma 2021/08
|
|
46.
|
その他
|
【再発および治療抵抗性造血器腫瘍の治療戦略】トータルセラピーから考えるレナリドミド抵抗性多発性骨髄腫に対する治療戦略 IMiDs-freeと抗CD38抗体-freeの意義と重要性 2021/08
|
|
47.
|
原著(症例報告除く)
|
Analysis of HLA haplotype and clinical factors during hematopoietic stem cell transplantation 2021/06
|
|
48.
|
原著(症例報告除く)
|
Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia 2021/06
|
|
49.
|
原著(症例報告除く)
|
Usefulness of Cytokine Gene Polymorphisms for the Therapeutic Choice in Japanese Patients with Rheumatoid Arthritis 2021/01
|
|
50.
|
原著(症例報告除く)
|
Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review 2021
|
|
51.
|
原著(症例報告除く)
|
Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis 2020/12
|
|
52.
|
症例報告
|
Refractory Chronic Lymphocytic Leukemia with
Central Nervous System Involvement: A Case
Report with Literature Review 2020/12
|
|
53.
|
その他
|
新規抗腫瘍薬と血栓症 2020/12
|
|
54.
|
その他
|
新規抗腫瘍療法と止血異常(第4回) エロツズマブと血小板減少 2020/12
|
|
55.
|
その他
|
造血幹細胞移植と血栓性合併症 2020/12
|
|
56.
|
その他
|
注目の全身性疾患 播種性血管内凝固(DIC) 2020/12
|
|
57.
|
原著(症例報告除く)
|
Mycophenolic acid, the active
form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and
type I IFN production by plasmacytoid dendritic cells. 2020/11
|
|
58.
|
原著(症例報告除く)
|
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry 2020/10
|
|
59.
|
原著(症例報告除く)
|
Extracellular Vesicle-Related Thrombosis in Viral Infection 2020/08
|
|
60.
|
原著(症例報告除く)
|
Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses 2020/08
|
|
61.
|
原著(症例報告除く)
|
Comparison of Starting Doses of Anagrelide as a First-Line Therapy in Patients With Cytoreductive Therapy-Naïve Essential Thrombocythemia: Difference Between Starting at 0.5 and 1.0 Mg/Day 2020/07
|
|
62.
|
その他
|
【造血器腫瘍の病態に基づいた新規治療薬の選択】多発性骨髄腫における抗体医薬エロツズマブ・ダラツムマブの作用機序および治療選択 2020/07
|
|
63.
|
その他
|
新規抗腫瘍療法と止血異常(第2回) IMiDsと血栓症 2020/06
|
|
64.
|
原著(症例報告除く)
|
ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma. 2020/03
|
|
65.
|
原著(症例報告除く)
|
Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting. 2020/02
|
|
66.
|
原著(症例報告除く)
|
Effect of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation 2019/12
|
|
67.
|
原著(症例報告除く)
|
Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation. 2019/12
|
|
68.
|
症例報告
|
Intravascular Large B-Cell Lymphoma; Our Experience with the Disease at Two Medical Centers 2019/12
|
|
69.
|
原著(症例報告除く)
|
Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era. 2019/12
|
|
70.
|
原著(症例報告除く)
|
輸血療法中にLISS-IATで不規則抗体が陽転化した2症例 2019/12
|
|
71.
|
原著(症例報告除く)
|
Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis. 2019/11
|
|
72.
|
症例報告
|
A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptoms. 2019/09
|
|
73.
|
原著(症例報告除く)
|
Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting. 2019/08
|
|
74.
|
原著(症例報告除く)
|
Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. 2019/08
|
|
75.
|
その他
|
Efficacy of CMV prophylaxis with letermovir early after transplantation. 2019/07
|
|
76.
|
原著(症例報告除く)
|
The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells. 2019/07
|
|
77.
|
原著(症例報告除く)
|
Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma. 2019/05
|
|
78.
|
原著(症例報告除く)
|
Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan. 2019/05
|
|
79.
|
原著(症例報告除く)
|
Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation. 2019/04
|
|
80.
|
原著(症例報告除く)
|
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience. 2019/03
|
|
81.
|
症例報告
|
Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia. 2019/03
|
|
82.
|
原著(症例報告除く)
|
GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. 2019/01
|
|
83.
|
原著(症例報告除く)
|
Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia. 2018/12
|
|
84.
|
その他
|
【多発性骨髄腫の治療】 多発性骨髄腫に対する免疫調節薬(IMiDs)の効果と作用機序 2018/11
|
|
85.
|
その他
|
セヴァリン療法の最適なアプローチと治療戦略 私はこう使っている 2018/10
|
|
86.
|
原著(症例報告除く)
|
Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia. 2018/09
|
|
87.
|
原著(症例報告除く)
|
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). 2018/09
|
|
88.
|
その他
|
【血小板減少症の病態と治療】 造血器腫瘍と血小板減少症 2018/09
|
|
89.
|
その他
|
新規治療薬を含めた骨髄腫に対する長期的な治療戦略 骨髄腫における1st Phase治療とNext Phase治療の意義 2018/09
|
|
90.
|
原著(症例報告除く)
|
Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study. 2018/08
|
|
91.
|
その他
|
自家末梢血幹細胞移植後のbrentuximab vedotin維持療法が奏効した高リスクHodgkinリンパ腫 2018/08
|
|
92.
|
原著(症例報告除く)
|
Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. 2018/07
|
|
93.
|
原著(症例報告除く)
|
The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. 2018/07
|
|
94.
|
その他
|
造血器腫瘍と免疫・凝固系(第3回) 多発性骨髄腫と免疫凝固異常 2018/06
|
|
95.
|
原著(症例報告除く)
|
Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia. 2018/05
|
|
96.
|
原著(症例報告除く)
|
Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm. 2018/04
|
|
97.
|
原著(症例報告除く)
|
Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma. 2018/01
|
|
98.
|
原著(症例報告除く)
|
How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia? 2018
|
|
99.
|
症例報告
|
Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma 2018
|
|
100.
|
症例報告
|
Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection. 2017/12
|
|
101.
|
原著(症例報告除く)
|
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor 2017/12
|
|
102.
|
原著(症例報告除く)
|
IgEと血小板関連インデックスの相関性 高IgE血症合併ITP症例を用いた検討 2017/12
|
|
103.
|
原著(症例報告除く)
|
SLEの合併したATLの一例 2017/12
|
|
104.
|
原著(症例報告除く)
|
胃癌を合併しATRAでコントロール良好となったAPL再発の一例 2017/12
|
|
105.
|
原著(症例報告除く)
|
腰部脊柱管狭窄症の手術を実施したITP症例 2017/12
|
|
106.
|
原著(症例報告除く)
|
Tyrosine kinase inhibitor and rituximab-CHOP treatment for concurrent chronic myeloid leukemia and non-Hodgkin lymphoma: a case report 2017/11
|
|
107.
|
症例報告
|
Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents. 2017/10
|
|
108.
|
原著(症例報告除く)
|
Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma 2017/09
|
|
109.
|
原著(症例報告除く)
|
Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation 2017/08
|
|
110.
|
原著(症例報告除く)
|
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience 2017/07
|
|
111.
|
その他
|
Thrombosis-related biomarkers in patients with multiple myeloma. 2017/05
|
|
112.
|
その他
|
Changes of acute GVHD-related biomarkers after allogeneic hematopoietic stem cell transplantation. 2017/03
|
|
113.
|
原著(症例報告除く)
|
Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era 2017/02
|
|
114.
|
原著(症例報告除く)
|
Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan. 2017/01
|
|
115.
|
症例報告
|
Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases 2016/12
|
|
116.
|
原著(症例報告除く)
|
Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA? 2016/11
|
|
117.
|
原著(症例報告除く)
|
再発・難治性B細胞リンパ腫患者に対する90Y-標識イブリツモマブ・チウキセタン療法の単施設における後方視的検討 2016/10
|
|
118.
|
症例報告
|
Bortezomibにより早期改善を認めたIgD骨髄腫関連高アンモニア脳症 2016/07
|
|
119.
|
症例報告
|
Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia 2016/07
|
|
120.
|
症例報告
|
Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma 2016/06
|
|
121.
|
原著(症例報告除く)
|
Guanosine and its modified derivatives are endogenous ligands for TLR7 2016/05
|
|
122.
|
原著(症例報告除く)
|
Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report 2016/02
|
|
123.
|
原著(症例報告除く)
|
Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation 2016/01
|
|
124.
|
その他
|
Induction and maintenance of Th2 immune responses by T-lymphocyte-derived microparticle. 2016
|
|
125.
|
原著(症例報告除く)
|
Associations between endothelial cell activation and acute GVHD after allogeneic hematopoietic stem cell transplantation 2015/11
|
|
126.
|
その他
|
悪性腫瘍と止血凝固異常(第5回) 慢性骨髄性白血病と血小板活性・血管内皮障害 2015/09
|
|
127.
|
症例報告
|
急性リンパ性白血病に発症した中枢神経原発移植後リンパ増殖性疾患 2015/08
|
|
128.
|
原著(症例報告除く)
|
スタチンの有する抗炎症効果 〜ヒト樹状細胞サブセットを治療ターケットとした新たな視点からの解析〜 2015/04
|
|
129.
|
その他
|
MESENCHYMAL TYPE GLIOMA STEM CELL EXPRESS ICOS LIGAND AND UPREGULATE ICOS+IL-10+T CELLS 2015
|
|
130.
|
原著(症例報告除く)
|
Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin 2015
|
|
131.
|
症例報告
|
治療抵抗性のITPに対し悪性リンパ腫の関与が疑われた一症例 2014/12
|
|
132.
|
その他
|
Immunotherapeutic effects of Ninjin-youei-to on patients with multiple myeloma. 2014/11
|
|
133.
|
その他
|
THERAPEUTIC CONCENTRATION OF TEMOZOLOMIDE DO NOT IMPAIR THE FUNCTION OF HUMAN DENDRITIC CELL SUBSETS 2014/11
|
|
134.
|
総説
|
"自然"炎症と凝固・血小板系のクロストーク(第12回) 免疫応答における血小板と樹状細胞 2014/09
|
|
135.
|
原著(症例報告除く)
|
IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand 2014/09
|
|
136.
|
総説
|
免疫応答における血小板と樹状細胞 2014/09
|
|
137.
|
症例報告
|
Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports 2014/07
|
|
138.
|
原著(症例報告除く)
|
Effect of temozomide on human dendritic cells. 2014/07
|
|
139.
|
その他
|
The preventive effects of recombinant thrombomodulin on transplantation-associated coagulopathy after allogeneic hematopoietic stem cell transplantation. 2014/07
|
|
140.
|
総説
|
トシリズマブ治療における血清IL-6の治療効果予測バイオマーカーとしての重要性 2014/06
|
|
141.
|
その他
|
Significance of anti-GPIIb/IIIa antibody in efficacy of eltrombopag for patients with immune thrombocytopenia 2014/04
|
|
142.
|
その他
|
造血器疾患と止血凝固(第5回) 骨髄異形成症候群と血小板機能 2014/03
|
|
143.
|
原著(症例報告除く)
|
Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis. 2013/07
|
|
144.
|
原著(症例報告除く)
|
Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming. 2013/03
|
|
145.
|
総説
|
アレルギー疾患におけるTSLP関連Th2細胞誘導機序 2013/03
|
|
146.
|
総説
|
樹状細胞とNK細胞の相互作用 2013/03
|
|
147.
|
原著(症例報告除く)
|
Recombinant thrombomodulin reduces the elevation of PAI-1 after allogeneic hematopoietic stem cell transplantation. 2013/02
|
|
148.
|
症例報告
|
血球貪食症候群を繰り返しDICを発症したNK/Tリンパ腫の一例 2013/02
|
|
149.
|
その他
|
骨髄異形成症候群と赤血球輸血 2013/02
|
|
150.
|
総説
|
樹状細胞サブセットの持つ2つのT細胞分化制御分子 OX40リガンド/ICOSリガンド発現バランスよる炎症性免疫応答制御 2013/02
|
|
151.
|
その他
|
血小板関連病態の診断治療 最近の話題 血小板と樹状細胞の免疫クロストーク 2012/11
|
|
152.
|
その他
|
血小板関連病態の診断治療：最近の話題 2012/11
|
|
153.
|
その他
|
Effective intravenous immunoglobulin therapy for Churge-Strauss syndrome (allergic granulomatous angiitis) complicated by neuropathy of the eighth cranial nerve: a case report. 2012/09
|
|
154.
|
その他
|
TGFβ(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. 2012/09
|
|
155.
|
その他
|
形質細胞様樹状細胞からのI型インターフェロン産生抑制による新たな自己免疫疾患の治療 2012/08
|
|
156.
|
その他
|
Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation. 2012/07
|
|
157.
|
その他
|
肺高血圧症最新薬物治療の実際-膠原病・肺疾患合併編-《肺疾患を合併した肺高血圧症に肺血管拡張薬は必要か?》ウルソデオキシコール酸の併用にてボセンタンによる肝機能障害を抑制し得た2症例 2012/07
|
|
158.
|
その他
|
Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients. 2012/06
|
|
159.
|
その他
|
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS co-stimulation of Foxp3+ T regulatory cells 2012/05
|
|
160.
|
その他
|
細胞機能とサイトカイン 樹状細胞の分化・機能発現とサイトカイン 2012/05
|
|
161.
|
その他
|
Cellular and Molecular Mechanisms of TSLP Function in Human Allergic Disorders - TSLP Programs the "Th2 code" in Dendritic Cells. 2012/03
|
|
162.
|
その他
|
血管内皮細胞とトロンボモジュリンの新機能 樹状細胞とトロンボモジュリン 2012/03
|
|
163.
|
その他
|
自己免疫疾患の新たな治療ターゲットとしてのplasmacytoid樹状細胞とI型インターフェロン 2012/03
|
|
164.
|
その他
|
反応する核酸の種類と樹状細胞サブセットの産生するサイトカイン 2012/03
|
|
165.
|
その他
|
Platelet-derived microparticles cause CD154-dependent activation of dendritic cells. 2012
|
|
166.
|
原著(症例報告除く)
|
Amelioration of 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice by immunoregulatory dendritic cells. 2011/12
|
|
167.
|
その他
|
樹状細胞サブセットによるIL-10産生Tr1細胞誘導の免疫制御 2011/11
|
|
168.
|
その他
|
スタチンと血管 樹状細胞によるインターフェロン誘導とスタチンの抑制効果 2011/09
|
|
169.
|
その他
|
膠原病関連血管炎によるびまん性肺胞出血に対してairway pressure-release ventilationを補助療法として使用し著効を認めた3症例 2011/09
|
|
170.
|
その他
|
形質細胞様樹状細胞をターゲットとした自己免疫疾患治療の新たな治療戦略 2011/07
|
|
171.
|
原著(症例報告除く)
|
A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. 2011/06
|
|
172.
|
その他
|
Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation? 2011/06
|
|
173.
|
原著(症例報告除く)
|
生物学的製剤導入に対する地域医療連携パス稼働下での生物学的製剤の選択および継続率 2011/06
|
|
174.
|
その他
|
Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus. 2011/03
|
|
175.
|
その他
|
The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. 2011/03
|
|
176.
|
その他
|
Interferon-α and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells. 2011/02
|
|
177.
|
その他
|
Dynamic role of cell-derived microparticles in hematopoietic stem cell transplantion 2011
|
|
178.
|
その他
|
Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. 2010/12
|
|
179.
|
その他
|
タクロリムスとミコフェノール酸モフェチルの併用療法が奏功した多剤抵抗性の全身性エリテマトーデスの一例 2010/09
|
|
180.
|
その他
|
Thymic stromal lymphopoietin plays an adjuvant role in BCG-mediated CD8(+) cytotoxic T cell responses through dendritic cell activation. 2010/08
|
|
181.
|
その他
|
Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and mice. 2010/07
|
|
182.
|
原著(症例報告除く)
|
The role of dendritic cell subsets in 2,4,6-trinitrobenzene sulfonic acid-induced ileitis 2010/06
|
|
183.
|
原著(症例報告除く)
|
長期休薬の後に発症したプロピルチオウラシル誘発性ANCA関連血管炎の一例 2010/06
|
|
184.
|
原著(症例報告除く)
|
Thymic Stromal Lymphopoietin-Activated Plasmacytoid Dendritic Cells Induce the Generation of FOXP3+ Regulatory T Cells in Human Thymus. 2010/05
|
|
185.
|
原著(症例報告除く)
|
Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. 2010/04
|
|
186.
|
その他
|
形質細胞様樹状細胞によるIL-10産生レギュラトリーT細胞の誘導 2010/04
|
|
187.
|
その他
|
Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sjögren's syndrome but not in the maintenance. 2010/03
|
|
188.
|
その他
|
Statins, inhibitors of HMG-CoA reductase, function as inhibitors for cellular and molecular components involved in type I IFN production. 2010/03
|
|
189.
|
その他
|
Dic (17;20) (p11;q11) Preceded MLL Gene Amplification in a Patient with de novo Mixed-Lineage Leukemia. 2010
|
|
190.
|
原著(症例報告除く)
|
アレルギー疾患に関連するサイトカイン群 6.TSLPで誘導されるアレルギー性炎症の制御 2009/12
|
|
191.
|
総説
|
樹状細胞を介する免疫応答制御 6.樹状細胞サブセットによるOX40リガンドおよびICOSリガンドを介する向炎症･抗炎症免疫応答の制御 2008/12
|
|
192.
|
原著(症例報告除く)
|
Mycobacterium bovis Bacillus Calmette-Guerin suppresses inflammatory Th2
responses by inducing functional alteration of TSLP-activated dendritic cells. 2008/10
|
|
193.
|
総説
|
OX40リガンドによるTr1細胞誘導の制御 2008/10
|
|
194.
|
原著(症例報告除く)
|
Successful treatment with plasma exchange in adult-onset Still's disease with hyper-IL-18-naemia and hyperallergic state. 2008/08
|
|
195.
|
原著(症例報告除く)
|
Two Functional Subsets of FOXP3＋ Regulatory T Cells in Human Thymus and Periphery 2008/06
|
|
196.
|
症例報告
|
縦隔気腫を合併した多発性筋炎・皮膚筋炎の3症例 2008/02
|
|
197.
|
原著(症例報告除く)
|
樹状細胞サブセットによるOX40リガンドおよびICOSリガンドを
介する向炎症・抗炎症免疫応答の制御 2008
|
|
198.
|
原著(症例報告除く)
|
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. 2007/12
|
|
199.
|
原著(症例報告除く)
|
Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. 2007/09
|
|
200.
|
その他
|
Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. 2007/01
|
|
201.
|
原著(症例報告除く)
|
Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. 2006/09
|
|
202.
|
その他
|
CX40 ligand shuts down IL-10-producing regulatory T cells. 2006
|
|
203.
|
その他
|
Human plasmacytoid pre-dendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand(GITRL). 2006
|
|
204.
|
その他
|
Maintenance and polarization of human TH2 central memory T cell by thymic stromal lymphopoietin activated dendritic cells. 2006
|
|
205.
|
その他
|
Plasmacytoid dendritic cell-specific ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. 2006
|
|
206.
|
その他
|
Specialization,kinetics,and repertoire of type 1 interferon responses by human plasmacytoid predendrritic cells. 2006
|
|
207.
|
その他
|
Hassall’ｓ corpuscles instruct dendritic cells to induce CD4+CD25+regulatory T cells in human thymun. 2005
|
|
208.
|
原著(症例報告除く)
|
IL-4-producing CD8(+) T cells may be an immunological hallmark of chronic GVHD. 2005
|
|
209.
|
その他
|
TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40ligand. 2005
|
|
210.
|
原著(症例報告除く)
|
Blood dendritic cells are decreased in acute graft-versus-host disease. 2004
|
|
211.
|
原著(症例報告除く)
|
Involvement of dendritic cells in sarcoidosis. 2004
|
|
212.
|
原著(症例報告除く)
|
Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. 2004
|
|
213.
|
その他
|
Plasmacytoid dendritic cellのもつT細胞制御機構 OX40 ligandとtype I IFN 2004
|
|
214.
|
総説
|
【樹状細胞の機能をめぐって】 ヒト樹状細胞サブセットと産生サイトカイン 2003/03
|
|
215.
|
その他
|
Analyses of dendritic cell subsets in pregnancy. 2003
|
|
216.
|
原著(症例報告除く)
|
Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. 2003
|
|
217.
|
総説
|
ヒト樹状細胞と疾患 2003
|
|
218.
|
原著(症例報告除く)
|
Comparison of bone marrow cells harvested from various bones of cynomolgus monkeys at various ages by perfusion or aspiration methods: a preclinical study for human BMT. 2002
|
|
219.
|
原著(症例報告除く)
|
Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. 2002
|
|
220.
|
原著(症例報告除く)
|
Marked increase in number of dendritic cells in autoimmune-prone (NZW x BXSB)F1 mice with age. 2002
|
|
221.
|
総説
|
Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. 2002
|
|
222.
|
総説
|
【樹状細胞をめぐって】 シェーグレン症候群と樹状細胞 2001/05
|
|
223.
|
原著(症例報告除く)
|
A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells. 2001
|
|
224.
|
原著(症例報告除く)
|
Alteration of peripheral blood dendritic cells in patients with primary Sjögren's syndrome. 2001
|
|
225.
|
原著(症例報告除く)
|
Differential regulation of human blood dendritic cell subsets by IFNs. 2001
|
|
226.
|
総説
|
【Th1/Th2バランス 基礎と臨床】 Th1/Th2分化における樹状細胞の役割 2001
|
|
227.
|
総説
|
マクロファージ･抗原提示細胞 DC1,DC2その分化と機能 2001
|
|
228.
|
総説
|
樹状細胞 免疫応答におけるその機能 2001
|
|
229.
|
総説
|
樹状細胞とTh1,Th2反応】 樹状細胞について 2001
|
|
230.
|
総説
|
【樹状細胞】 血液疾患と樹状細胞 2000/06
|
|
231.
|
原著(症例報告除く)
|
HGF activates signal transduction from EPO receptor on human cord blood CD34+/CD45+ cells 1999
|
|
5件表示
|
|
全件表示(231件)
|
